The *Journal of Psychiatry & Neuroscience* is indexed according to the medical subject headings established by the National Library of Medicine, US National Institutes of Health. The title for each article is followed by a code that designates the article’s category. The categories used in this volume are listed below.

La *Revue de psychiatrie & de neuroscience* est indexée par vedette-matière selon la nomenclature de la National Library of Medicine des National Institutes of Health américains.

Chaque titre d’article est suivi d’un code indiquant à quelle catégorie l’article appartient. Les catégories utilisées dans ce volume sont les suivantes:

- **Rev** / **Revue de psychiatrie & de neuroscience** (Psychopharm)
- **Res** / **Research Paper** (CRSN)
- **E** / **Editorial** (CRSN)
- **CRSN** / **CRSN Symposium** (CRSN)
- **CCNP** / **CCNP News and Views** (CCNP)
- **Comm** / **Commentary** (CCNP)
- **Brief** / **Brief Report** (CCNP)

### Subjects / Sujets

**Acetylcholine**

Interactions between β-amyloid and central cholinergic neurons: implications for Alzheimer’s disease (Kar and others) (Rev) 427

The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

**Adolescent**

Should cognitive deficit be a diagnostic criterion for schizophrenia? (Lewis) (Rev) 102

With all the recent concern about SSRIs and suicidality, what advice should be given to the practising clinician regarding the management of a depressed young person? (Lapiere) (Psychopharm) 406

**Alzheimer disease**

Interactions between β-amyloid and central cholinergic neurons: implications for Alzheimer’s disease (Kar and others) (Rev) 427

**Amyloid**

Interactions between β-amyloid and central cholinergic neurons: implications for Alzheimer’s disease (Kar and others) (Rev) 427

**Anorexia nervosa**

Eating disorders and the serotonin connection: state, trait and developmental effects (Steiger) (Rev) 20

**Anti-anxiety agents**

Although antidepressants and anxiolytics are frequently used together to treat depression in the acute phase, how effective is the concomitant use of these drugs? (Kanba) (Psychopharm) 485

**Anticonvulsants**

What exactly is a mood stabilizer? (Young) (E) 87

**Antidepressive agents**

Although antidepressants and anxiolytics are frequently used together to treat depression in the acute phase, how effective is the concomitant use of these drugs? (Kanba) (Psychopharm) 485

Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors (Bourin and others) (Res) 126

How many good antidepressant medications have we missed? (Blier) (E) 248

**Antipsychotic agents**

Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia (Lane and others) (Res) 30

Olanzapine in the treatment of pervasive developmental disorders: a case series analysis (Stavrakaki and others) (Brief) 57

Potential benefits of quetiapine in the treatment of substance dependence disorders (Sattar and others) (Res) 452

Tardive dyskinesia in 2 patients treated with ziprasidone (Ananth and others) (Brief) 467

The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Using animal models to test a neurodevelopmental hypothesis of schizophrenia (Lipska) (CRSN) 282

What exactly is a mood stabilizer? (Young) (E) 87

**Anxiety disorders**

The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

**Apoptosis**

Glyceraldehyde-3-phosphate dehydrogenase as a target for small-molecule disease-modifying therapies in human neurodegenerative disorders (Berry) (Comm) 337

**Autistic disorder**

The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

**Benzodiazepines**

The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

**Bipolar disorder**

Does lithium save lives? (Joffe) (E) 9

Gene–environment interaction and the genetics of depression (Lesch) (CRSN) 174

Implication des gènes du système sérotoninergique dans la vulnérabilité aux conduites suicidaires (Courtet and others) (Rev) 350

Should cognitive deficit be a diagnostic criterion for schizophrenia? (Lewis) (Rev) 102

What exactly is a mood stabilizer? (Young) (E) 87

**Brain**

Transcranial magnetic stimulation (TMS) of the human frontal cortex: implications for repetitive TMS treatment of depression (Paus and Barrett) (CRSN) 268

**Brain-derived neurotrophic factor**

Postmortem investigations of the pathophysiology of...
Eating disorders with binge-eating behaviour are associated with Nitric oxide: A key player in the relation between cardiovascular disease and major depressive disorder? (Le Mellédo and others) (E) 414

Case–control studies
Eating disorders with binge-eating behaviour are associated with the s allele of the 3′-UTR VNTR polymorphism of the dopamine transporter gene (Shinohara and others) (Brief) 134

Catechol-O-methyltransferase
Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes (Perlam and others) (CRSN) 287

Child
Should cognitive deficit be a diagnostic criterion for schizophrenia? (Lewis) (Rev) 102
With all the recent concern about SSRIs and suicidality, what advice should be given to the practising clinician regarding the management of a depressed young person? (Lapierre) (Psychopharm) 406

Child development disorders, pervasive
Olanzapine in the treatment of pervasive developmental disorders: a case series analysis (Stavrakaki and others) (Brief) 57

Choline
The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Chorioamnionitis
The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Clinical trials
How many good antidepressant medications have we missed? (Blier) (E) 248

Cocaine
Heroin and cocaine co-use in a group of injection drug users in Montréal (Leri and others) (Res) 40

Codes of ethics
Ethical conduct of journal editors (Young and Joffe) (E) 334

Cognition
Should cognitive deficit be a diagnostic criterion for schizophrenia? (Lewis) (Rev) 102
Transcranial magnetic stimulation (TMS) of the human frontal cortex: implications for repetitive TMS treatment of depression (Paus and Barrett) (CRSN) 268

Corticotropin
Implication of the hypothalamic–pituitary–adrenal axis in the physiopathology of depression (Barden) (CRSN) 185

Corticotropin-releasing factor
Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission (Tringali and others) (Res) 459

- D -

Delusions
Cotard’s syndrome with schizophreniform disorder can be successfully treated with electroconvulsive therapy: case report (Caliyurt and others) (Brief) 138

Depression
Gene–environment interaction and the genetics of depression (Lesch) (CRSN) 174
Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response (Blier and others) (CRSN) 208
Implication des gènes du système sérotoninergique dans la vulnérabilité aux conduites suicidaires (Courtet and others) (Rev) 350
Implication of the hypothalamic–pituitary–adrenal axis in the physiopathology of depression (Barden) (CRSN) 185
Implications of adult hippocampal neurogenesis in antidepressant action (Malberg) (CRSN) 196

Neurobiology of severe mental disorders: from cell to bedside
25th International Symposium of the Centre de recherche en sciences neurologiques, Université de Montréal (Rompé and others) (E) 167

Nitric oxide: A key player in the relation between cardiovascular disease and major depressive disorder? (Le Mellédo and others) (E) 414

Peripheral thyroid hormones and response to selective serotonin reuptake inhibitors (Gittin and others) (Res) 383

The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-α-induced depression (Wichers and Maes) (Rev) 11

The role of the hippocampus in the pathophysiology of major depression (Campbell and MacQueen) (Rev) 417

Testing the association between thyroid dysfunction and psychiatric diagnostic group in an iodine-deficient area (Herrmann and others) (Res) 444

The therapeutic role of 5-HT1A and 5-HT1B receptors in depression (Celada and others) (CRSN) 252

Transcranial magnetic stimulation (TMS) of the human frontal cortex: implications for repetitive TMS treatment of depression (Paus and Barrett) (CRSN) 268

The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Diagnosis
Should cognitive deficit be a diagnostic criterion for schizophrenia? (Lewis) (Rev) 102

Dopamine
Eating disorders with binge-eating behaviour are associated with the s allele of the 3′-UTR VNTR polymorphism of the dopamine transporter gene (Shinohara and others) (Brief) 134

Glutamate co-transmission as an emerging concept in monoamine neuron function (Trudeau) (CRSN) 296

Olanzapine in the treatment of pervasive developmental disorders: a case series analysis (Stavrakaki and others) (Brief) 57

Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes (Perlam and others) (CRSN) 287

The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Dorsal raphe nucleus
The therapeutic role of 5-HT1A and 5-HT1B receptors in depression (Celada and others) (CRSN) 252

Drug-induced
Tardive dyskinesia in 2 patients treated with ziprasidone (Ananth and others) (Brief) 467

Drug therapy
Does lithium save lives? (Joffe) (E) 9

Glyceraldehyde-3-phosphate dehydrogenase as a target for
small-molecule disease-modifying therapies in human neurodegenerative disorders (Berry) (Comm) 337
What exactly is a mood stabilizer? (Young) (E) 87

**Dyskinesia**
Tardive dyskinesia in 2 patients treated with ziprasidone (Ananth and others) (Brief) 467

**Eating disorders**
Eating disorders and the serotonin connection: state, trait and developmental effects (Steiger) (Rev) 20
Eating disorders with binge-eating behaviour are associated with the s allele of the 3'-UTR VNTR polymorphism of the dopamine transporter gene (Shinohara and others) (Brief) 134

**Electroconvulsive therapy**
Successful treatment with electroconvulsive therapy: case report (Caliyurt and others) (Brief) 138
Transcranial magnetic stimulation (TMS) of the human frontal cortex: implications for repetitive TMS treatment of depression (Paus and Barrett) (CRSN) 268
The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

**Environment**
Gene–environment interaction and the genetics of depression (Lesch) (CRSN) 174

**Evoked potential**
Semantics and N400: insights for schizophrenia (Kumar and Debruille) (Rev) 89

**Fetal alcohol syndrome**
The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

**Frontal lobe**
Transcranial magnetic stimulation (TMS) of the human frontal cortex: implications for repetitive TMS treatment of depression (Paus and Barrett) (CRSN) 268

**Gamma-aminobutyric acid**
The therapeutic role of 5-HT₁ and 5-HT₂ receptors in depression (Celada and others) (CRSN) 252
The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470
Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission (Tringali and others) (Res) 459

**Gene expression**
Gene–environment interaction and the genetics of depression (Lesch) (CRSN) 174
Implication des gènes du système sérotoninergique dans la vulnérabilité aux conduites suicidaires (Courtet and others) (Rev) 350

**Genetic predisposition to disease**
Eating disorders with binge-eating behaviour are associated with the s allele of the 3'-UTR VNTR polymorphism of the dopamine transporter gene (Shinohara and others) (Brief) 134
Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes (Perlman and others) (CRSN) 287

**Genetics**
Gene–environment interaction and the genetics of depression (Lesch) (CRSN) 174
Implication des gènes du système sérotoninergique dans la vulnérabilité aux conduites suicidaires (Courtet and others) (Rev) 350

**Glucocorticoids**
Mother to infant or infant to mother? Reciprocal regulation of responsiveness to stress in rodents and the implications for humans (Walker and others) (Rev) 364
The role of the hippocampus in the pathophysiology of major depression (Campbell and MacQueen) (Rev) 417

**Glutamate**
Glutamate co-transmission as an emerging concept in monoamine neuron function (Trudeau) (CRSN) 296
Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes (Perlman and others) (CRSN) 287
The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

**Glyceraldehyde-3-phosphate dehydrogenase**
Glyceraldehyde-3-phosphate dehydrogenase as a target for small-molecule disease-modifying therapies in human neurodegenerative disorders (Berry) (Comm) 337

**Growth and development**
Mother to infant or infant to mother? Reciprocal regulation of responsiveness to stress in rodents and the implications for humans (Walker and others) (Rev) 364

**Heroin**
Heroin and cocaine co-use in a group of injection drug users in Montréal (Leri and others) (Res) 40

**Hippocampus**
Implications of adult hippocampal neurogenesis in antidepressant action (Malberg) (CRSN) 196
The role of the hippocampus in the pathophysiology of major depression (Campbell and MacQueen) (Rev) 417
Using animal models to test a neurodevelopmental hypothesis of schizophrenia (Lipska) (CRSN) 282

**Human development**
Mother to infant or infant to mother? Reciprocal regulation of responsiveness to stress in rodents and the implications for humans (Walker and others) (Rev) 364

**Hypothalamus**
Implication of the hypothalamic–pituitary–adrenal axis in the pathophysiology of depression (Barden) (CRSN) 185
Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission (Tringali and others) (Res) 459

**Interferon-alpha**
The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-α-induced depression (Wichers and Maes) (Rev) 11
Iodine
Testing the association between thyroid dysfunction and psychiatric diagnostic group in an iodine-deficient area (Hermann and others) (Res) 444

- L -

Lactation
Mother to infant or infant to mother? Reciprocal regulation of responsiveness to stress in rodents and the implications for humans (Walker and others) (Rev) 364

Leptin
Mother to infant or infant to mother? Reciprocal regulation of responsiveness to stress in rodents and the implications for humans (Walker and others) (Rev) 364

Ligands
Orphanin FQ/nociceptin suppresses motor activity through an action along the mesoaccumbens axis in rats (Narayan and others) (Res) 116

Lithium
Does lithium save lives? (Joffe) (E) 9
The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470
What exactly is a mood stabilizer? (Young) (E) 87

Medial prefrontal cortex
The therapeutic role of 5-HT IA and 5-HT IB receptors in depression (Celada and others) (CRSN) 252

Melatonin
Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors (Bourin and others) (Res) 126

Memory
The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Menopause
The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Mice
Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors (Bourin and others) (Res) 126
Mother to infant or infant to mother? Reciprocal regulation of responsiveness to stress in rodents and the implications for humans (Walker and others) (Rev) 364

Microdialysis
The therapeutic role of 5-HT IA and 5-HT IB receptors in depression (Celada and others) (CRSN) 252

Models, animal
Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors (Bourin and others) (Res) 126
Gene–environment interaction and the genetics of depression (Lesch) (CRSN) 174
Glutamate co-transmission as an emerging concept in monoamine neuron function (Trudeau) (CRSN) 296
Implication of the hypothalamic–pituitary–adrenal axis in the physiopathology of depression (Barden) (CRSN) 185
Implications of adult hippocampal neurogenesis in antidepressant action (Malberg) (CRSN) 196
Interactions between β-amyloid and central cholinergic neurons: implications for Alzheimer’s disease (Kar and others) (Rev) 427
Mother to infant or infant to mother? Reciprocal regulation of responsiveness to stress in rodents and the implications for humans (Walker and others) (Rev) 364
Neurobiology of severe mental disorders: from cell to bedside. 25th International Symposium of the Centre de recherche en sciences neurologiques, Université de Montréal (Rompré and others) (E) 167
Orphanin FQ/nociceptin suppresses motor activity through an action along the mesoaccumbens axis in rats (Narayan and others) (Res) 116
The role of the hippocampus in the pathophysiology of major depression (Campbell and MacQueen) (Rev) 417
The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470
Using animal models to test a neurodevelopmental hypothesis of schizophrenia (Lipska) (CRSN) 282
Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission (Tringali and others) (Res) 459

Mood disorders
Testing the association between thyroid dysfunction and psychiatric diagnostic group in an iodine-deficient area (Hermann and others) (Res) 444
Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission (Tringali and others) (Res) 459

Motivation
The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Motor activity
Orphanin FQ/nociceptin suppresses motor activity through an action along the mesoaccumbens axis in rats (Narayan and others) (Res) 116

Neurodegenerative diseases
Glyceraldehyde-3-phosphate dehydrogenase as a target for small-molecule disease-modifying therapies in human neurodegenerative disorders (Berry) (Comm) 337
Interactions between β-amyloid and central cholinergic neurons: implications for Alzheimer’s disease (Kar and others) (Rev) 427

Neuromodulation
Interactions between β-amyloid and central cholinergic neurons: implications for Alzheimer’s disease (Kar and others) (Rev) 427

Neurons
Implications of adult hippocampal neurogenesis in antidepressant action (Malberg) (CRSN) 196
The role of the hippocampus in the pathophysiology of major depression (Campbell and MacQueen) (Rev) 417
Using animal models to test a neurodevelopmental hypothesis of schizophrenia (Lipska) (CRSN) 282

Nicotine
The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Nitric oxide
Nitric oxide: A key player in the relation between cardiovascular disease and major depressive disorder? (Le Mellédo and others) (E) 167

Norepinephrine
Glutamate co-transmission as an emerging concept in monoamine neuron function (Trudeau) (CRSN) 296
Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant /anxiolytic response (Blier and others) (CRSN) 208
Index au volume 29

Nucleus accumbens
Orphanin FQ/nociceptin suppresses motor activity through an action along the mesoaccumbens axis in rats (Narayanan and others) (Res) 116
Using animal models to test a neurodevelopmental hypothesis of schizophrenia (Lipska) (CRSN) 282

Phototherapy
The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Pindolol
The therapeutic role of 5-HT1A and 5-HT1B receptors in depression (Celada and others) (CRSN) 252

Pituitary–adrenal system
Implication of the hypothalamic–pituitary–adrenal axis in the physiopathology of depression (Barden) (CRSN) 185

Placebos
How many good antidepressant medications have we missed? (Blier) (E) 248

Policy making
The physician–scientist in Canadian psychiatry (Honer and Linseman) (Res) 49

Prefrontal cortex
Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes (Perlman and others) (CRSN) 287
Using animal models to test a neurodevelopmental hypothesis of schizophrenia (Lipska) (CRSN) 282

Premenstrual syndrome
The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Psychotic disorders
Cotard’s syndrome with schizophreniform disorder can be successfully treated with electroconvulsive therapy: case report (Calliyurt and others) (Brief) 138
Should cognitive deficit be a diagnostic criterion for schizophrenia? (Lewis) (Rev) 102

Psychotropic drugs
The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Publishing
Ethical conduct of journal editors (Young and Joffe) (E) 334

Quetiapine
Potential benefits of quetiapine in the treatment of substance dependence disorders (Sattar and others) (Res) 452

Randomized controlled trials
How many good antidepressant medications have we missed? (Blier) (E) 248

Rats
Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors (Bourin and others) (Res) 126
Mother to infant or infant to mother? Reciprocal regulation of responsiveness to stress in rodents and the implications for humans (Walker and others) (Rev) 364

Orphanin FQ/nociceptin suppresses motor activity through an action along the mesoaccumbens axis in rats (Narayanan and others) (Res) 116

Receptors, adrenergic
Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response (Blier and others) (CRSN) 208

Receptors, AMPA
The therapeutic role of 5-HT1A and 5-HT1B receptors in depression (Celada and others) (CRSN) 252

Receptors, glucocorticoid
Implication of the hypothalamic–pituitary–adrenal axis in the physiopathology of depression (Barden) (CRSN) 185

Receptors, neurokinin-1
Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response (Blier and others) (CRSN) 208

Receptors, opioid
Orphanin FQ/nociceptin suppresses motor activity through an action along the mesoaccumbens axis in rats (Narayanan and others) (Res) 116

Research
The physician–scientist in Canadian psychiatry (Honer and Linseman) (Res) 49

Risperidone
Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia (Lane and others) (Res) 30

Schizophrenia
Glutamate co-transmission as an emerging concept in monoamine neuron function (Trudeau) (CRSN) 296
Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia (Lane and others) (Res) 30
Neurobiology of severe mental disorders: from cell to bedside. 25th International Symposium of the Centre de recherche en sciences neurologiques, Université de Montréal (Rompré and others) (E) 167
Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes (Perlman and others) (CRSN) 287
Should cognitive deficit be a diagnostic criterion for schizophrenia? (Lewis) (Rev) 102
Tardive dyskinesia in 2 patients treated with ziprasidone (Ananth and others) (Brief) 467
The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470
Using animal models to test a neurodevelopmental hypothesis of schizophrenia (Lipska) (CRSN) 282
What is the role of pharmacotherapy in tobacco cessation in patients with schizophrenia? (Els) (Psychopharm) 240

Schizophrenia and disorders with psychotic features
Semantics and N400: insights for schizophrenia (Kumar and Debruille) (Rev) 89

Semantics
Semantics and N400: insights for schizophrenia (Kumar and Debruille) (Rev) 89

Serotonin
Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors (Bourin and others) (Res) 126
Eating disorders and the serotonin connection: state, trait and developmental effects (Steiger) (Rev) 20
Gene–environment interaction and the genetics of depression (Lesch) (CRSN) 174
Index to Volume 29

J Psychiatry Neurosci 2004;29(6)
Tyrosine hydroxylase
Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes (Perlman and others) (CRSN) 287

Valproic acid
Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission (Tringali and others) (Res) 459

What exactly is a mood stabilizer? (Young) (E) 87

Ventral tegmental area
Orphanin FQ/nociceptin suppresses motor activity through an action along the mesoaccumbens axis in rats (Narayanan and others) (Res) 116

Ziprasidone
Tardive dyskinesia in 2 patients treated with ziprasidone (Ananth and others) (Brief) 467

Authors / Auteurs

Adell A See Celada P Jt Auth
Akil M See Perlman WR Jt Auth
Altschuler LL See Gillin M Jt Auth
Amargós-Bosh M See Celada P Jt Auth
Ananth J, Burgoyne KS, Niz D, Smith M Tardive dyskinesia in 2 patients treated with ziprasidone (Brief) 467
Antochi R See Stavrakaki C Jt Auth
Artigas F See Celada P Jt Auth
Astruc B See Courtet P Jt Auth
Aubry JM See Tringali G Jt Auth

Baker GB See Le Mellédo JM Jt Auth
Barden N Implication of the hypothalamic–pituitary–adrenal axis in the physiopathology of depression (CRSN) 185
Barrett J See Paus T Jt Auth
Bauer M See Gillin M Jt Auth
Berry MD Glyceraldehyde-3-phosphate dehydrogenase as a target for small-molecule disease-modifying therapies in human neurodegenerative disorders (Comm) 337
Bhatia SC See Sattar SP Jt Auth
Blier P How many good antidepressant medications have we missed? (E) 248
Bourin M, Mocaër E, Porsolt R Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors (Res) 126
Bruneau J See Leri F Jt Auth
Buresi C See Courtet P Jt Auth
Burgoyne KS See Ananth J Jt Auth

Caliyurt O, Vardar E, Tuglu C Cotard’s syndrome with schizophreniaiform disorder can be successfully treated with electroconvulsive therapy: case report (Brief) 138

Campbell S, MacQueen G The role of the hippocampus in the pathophysiology of major depression (Rev) 417

Carroll FI See Narayanan S Jt Auth

Castelnaud D See Courtet P Jt Auth
Celada P, Puig MV, Amargós-Bosh M, Adell A, Artigas F The therapeutic role of 5-HT_{1A} and 5-HT_{1B} receptors in depression (CRSN) 252
Courtet P, Jollant F, Castelnaud D, Astruc B, Buresi C, Malafosse A Implication des gènes du système sérotoninergique dans la vulnérabilité aux conduites suicidaires (Rev) 350

Debruille JB See Kumar N Jt Auth
Deschamps S See Walker CM Jt Auth

Els C What is the role of pharmacotherapy in tobacco cessation in patients with schizophrenia? (Psychopharm) 240

Emery PC See Stavrakaki C Jt Auth

Fairbanks L See Gillin M Jt Auth
Flores C, Paine T, Srivistava LK, Leyton M The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (CCNP) 470

Frye MA See Gillin M Jt Auth

Gallo-Payet N See Walker CM Jt Auth

Gobbi G See Blier P Jt Auth

Haddjeri N See Blier P Jt Auth
Hen R See Blier P Jt Auth
Hermann D, Hewer W, Lederbogen F Testing the association between thyroid dysfunction and psychiatric diagnostic group in an iodine-deficient area (Res) 444

Hewer W See Hermann D Jt Auth
Hiejima Y See Shinohara M Jt Auth

Higuchi T What are the diagnostic criteria, therapy and prophylaxis for discontinuation symptoms due to SSRI? (Psychopharm) 160
Hirano M See Shinohara M Jt Auth
Huner WG, Linseman MA
The physician–scientist in Canadian psychiatry (Res) 49
Huynh EL See Gitlin M Jt Auth
- J -
Joffe RT
Does lithium save lives? (E) 9
Joffe RT See Young SN Jt Auth
Jollant F See Courtet P Jt Auth
- K -
Kanba S
Although antidepressants and anxiolytics are frequently used together to treat depression in the acute phase, how effective is the concomitant use of these drugs? (Psychopharm) 485
Kanba S See Shinohara M Jt Auth
Kar S, Slowikowski SPM, Westaway D, Mount HTJ
Interactions between β-amyloid and central cholinergic neurons: implications for Alzheimer’s disease (Rev) 427
Kleinman JE See Perlman WR Jt Auth
Korenman S See Gitlin M Jt Auth
Kumar N, Debruille JB
Semantics and N400: insights for schizophrenia (Rev) 89
- L -
Lam H See Narayanan S Jt Auth
Lane CJ, Ngan ETC, Yatham LN, Ruth TJ, Liddle PF
Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia (Res) 30
Lapiere YD
With all the recent concern about SSRIs and suicidality, what advice should be given to the practising clinician regarding the management of a depressed young person? (Psychopharm) 406
Le Mellédo JM, Mahil N, Baker GB
Nitric oxide: A key player in the relation between cardiovascular disease and major depressive disorder? (E) 414
Lederbogen F See Hermann D Jt Auth
Leri F, Stewart J, Tremblay A, Bruneau J
Heroin and cocain co-use in a group of injection drug users in Montréal (Res) 40
Lesch KP
Gene–environment interaction and the genetics of depression (CRSN) 174
Lewis R
Should cognitive deficit be a diagnostic criterion for schizophrenia? (Rev) 102
Leyton M See Flores C Jt Auth
Liddle PF See Lane CJ Jt Auth
Linseman MA See Honer WG Jt Auth
Lipska BK
Using animal models to test a neurodevelopmental hypothesis of schizophrenia (CRSN) 282
Lupien S See Walker CM Jt Auth
Lutfy K See Narayanan S Jt Auth
- M -
MacQueen G See Campbell S Jt Auth
Maes M See Wichers MC Jt Auth
Mahil N See Le Mellédo JM Jt Auth
Malafosse A See Courtet P Jt Auth
Malberg JE
Implications of adult hippocampal neurogenesis in antidepressant action (CRSN) 196
Mathew G See Blier P Jt Auth
Mizushima H See Shinohara M Jt Auth
Mocaër E See Bourin M Jt Auth
Moscione K See Tringali G Jt Auth
Mount HTJ See Kar S Jt Auth
- N -
Nakazawa M See Shinohara M Jt Auth
Narayanan S, Lam H, Carroll FI, Lutfy K
Orphanin FQ/nociceptin suppresses motor activity through an action along the mesoaccumbens axis in rats (Res) 116
Navarra P See Tringali G Jt Auth
Ngan ETC See Lane CJ Jt Auth
Niz D See Ananth J Jt Auth
- O -
Ono Y See Shinohara M Jt Auth
- P -
Paine T See Flores C Jt Auth
Paus R, Barrett J
Transcranial magnetic stimulation (TMS) of the human frontal cortex: implications for repetitive TMS treatment of depression (CRSN) 268
Perlman WR, Weickert CS, Akil M, Kleinman JE
Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes (CRSN) 287
Petty F See Sattar SP Jt Auth
Porsolt R See Bourin M Jt Auth
Pozzoli G See Tringali G Jt Auth
Preziosi P See Tringali G Jt Auth
Proulx K See Walker CM Jt Auth
Puig MV See Celada P Jt Auth
- R -
Richard D See Walker CM Jt Auth
Rompré PP, Stip E, Trudeau LÉ
Neurobiology of severe mental disorders: from cell to bedside. 25th International Symposium of the Centre de recherche en sciences neurologiques, Université de Montréal (E) 167
Ruth TJ See Lane CJ Jt Auth
- S -
Salzman C See Walker CM Jt Auth
Santarelli L See Blier P Jt Auth
Sattar SP, Bhatia SC, Petty F
Potential benefits of quetiapine in the treatment of substance dependence disorders (Res) 452
Eating disorders with binge-eating behaviour are associated with the s allele of the 3'UTR VNTR polymorphism of the dopamine transporter gene (Brief) 134
Shioe K See Shinohara M Jt Auth  
Slowikowski SPM See Kar S Jt Auth  
Smith M See Ananth J Jt Auth  
Srivastava LK See Flores C Jt Auth  
Stavrakaki C, Antochi R, Emery PC  
Olanzapine in the treatment of pervasive developmental disorders: a case series analysis (Brief) 57  
Steiger H  
Eating disorders and the serotonin connection: state, trait and developmental effects (Rev) 20  
Stewart J See Leri F Jt Auth  
Stip E See Rompré PP Jt Auth  
Suri R See Gitlin M Jt Auth  

- T -  
Tremblay A See Leri F Jt Auth  
Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission (Res) 459  
Trudeau LÉ  
Glutamate co-transmission as an emerging concept in monoamine neuron function (CRSN) 296  
Trudeau LÉ See Rompré PP Jt Auth  
Tu M See Walker CM Jt Auth  
Tuglu C See Caliyurt O Jt Auth  

- V -  
Vairano M See Tringali G Jt Auth  
Vardar E See Caliyurt O Jt Auth  

- W -  
Mother to infant or infant to mother? Reciprocal regulation of responsiveness to stress in rodents and the implications for humans (Rev) 364  
Weickert CS See Perlman WR Jt Auth  
Westaway D See Kar S Jt Auth  
Wichers MC, Maes M  
The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-α-induced depression (Rev) 11  
Woodside B See Walker CM Jt Auth  

- Y -  
Yatham LN See Lane CJ Jt Auth  
Young LT  
What exactly is a mood stabilizer? (E) 87  
Young SN, Joffe RT  
Ethical conduct of journal editors (E) 334  

- Z -  
Zamori C See Tringali G Jt Auth